The Novavax 4/14/09 press release http://www.novavax.com/download/releases/Pan%204_14_09%20FO.pdf

NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains H1N1 Virus-like Particle (VLP) Vaccine Candidate Based on the 1918 Spanish Influenza Strain Protected Mice and Ferrets Against the Spanish Flu and Highly Pathogenic H5N1 Bird Flu ROCKVILLE, MD (April 14, 2009) - Novavax, Inc. (NASDAQ:NVAX) today reported preclinical study results showing that an investigational H1N1 virus-like particle (VLP) vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain. The study, published in the March 25, 2009 online issue of the Journal of Virology, was conducted by scientists from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA and Novavax under a Collaborative Research and Development Agreement. ...

First they dug up the corpses of people who died from the 1918 Spanish flu, then they revived the virus and then produced the vaccince - which I will most certainly NOT be taking.